NLCA
National Lung Cancer Audit

Summary of results for patients diagnosed in Wales 2024

Key
- improving from 2023
- worsening from 2023
- unchanged from 2023

Diagnosis & staging

2,135 patients were diagnosed with lung cancer in 2024

2,334 in 2023 & 2,211 in 2022

51% female

49% male

73 years median age at diagnosis

35% of patients were diagnosed at **stage 1-2**
34% in 2023 & 30% in 2022

44% of patients presented **with stage 4 lung cancer**
45% in 2023 & 47% in 2022

26% of patients were diagnosed **after emergency admission**
27% in 2023 & 29% in 2022

Waiting times in NSCLC

91 days Median time from referral to **surgery** in NSCLC stage 1-2

97 days in 2023

76 days Median time from referral to **SACT** in NSCLC stage 3B-4

78 days in 2023

Treatment allocation

Treatment with curative intent for Non-Small Cell Lung Cancer (NSCLC)

78% of patients with NSCLC (stage 1-2, Performance Status (PS) 0-2) received treatment with curative intent*

≥80% Audit standard

77% in 2023
76% in 2022

*surgery or radical radiotherapy

62% of patients with NSCLC (stage 3A, PS 0-2) received treatment with curative intent**

N/A

67% in 2023
61% in 2022

**surgery, radical radiotherapy or multimodal combination with chemotherapy

Surgery for Non-Small Cell Lung Cancer (NSCLC)

17% of patients with NSCLC had surgical treatment for their cancer

≥17% Audit standard

18% in 2023
14% in 2022

Absolute number of surgeries in 2024: 1,910

Systemic Anti-Cancer Therapy (SACT) for Non-Small Cell Lung Cancer (NSCLC)

62% of patients with NSCLC (stage 3B-4, PS 0-1) received SACT

≥70% Audit standard

55% in 2023
60% in 2022

Systemic Anti-Cancer Therapy (SACT) for Small Cell Lung Cancer (SCLC)

60% of patients with SCLC received treatment with SACT

≥70% Audit standard

65% in 2023
71% in 2022

Median time from 'decision to treat' to start SACT: 21 days

Survival outcomes

2,135 patients were diagnosed between 1 January and 31 December 2024. For these patients:

Median survival

350 days

301 days in 2023
262 days in 2022

One year survival

49%

46% in 2023
43% in 2022

Data quality

Completeness of key routine data items

	Stage	Performance status	Basis of diagnosis	Morphology	Lung Clinical Nurse Specialist at diagnosis	Smoking status
	97%	98%	100%	99%	98%	72%
	90% ✓ Audit standard	90% ✓ Audit standard	90% ✓ Audit standard	75% ✓ Audit standard	90% ✓ Audit standard	90% ✗ Audit standard